author-photo

Pierre Laneuville

McGill University Health Centre

44

Papers

1099

Citations

Citation Trend

Filter By

Papers (33) Sort By

Journal Conference Others

BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group.

2021 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (1)
Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.

2020 Current Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
BCR-ABL1 qPCR-Based Doubling Time within the First 6 Months after Imatinib Discontinuation Is a Predictive of Successful TKI Treatment-Free Remission

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL: PF410

2019
Show All
- Source
- Cite
- Save
Citations (0)